What is Cyted Health?
Cyted Health operates at the intersection of advanced biotechnology and clinical diagnostics, specifically targeting the complex challenges associated with gastrointestinal health. Based in Cambridge, England, the company has developed a sophisticated platform designed to improve the detection and management of digestive conditions. By integrating cutting-edge scientific research with scalable diagnostic workflows, Cyted Health provides healthcare providers with actionable insights that facilitate earlier intervention and improved patient outcomes. The company's market position is defined by its focus on high-impact medical technology, positioning it as a critical partner for healthcare systems seeking to optimize gastrointestinal care through precision medicine.
How much funding has Cyted Health raised?
Cyted Health has raised a total of $43.5M across 1 funding round:
Series B
$43.5M
Series B (2025): $43.5M with participation from The Morningside Group, British Business Bank, BGF, EQT, and Advent Life Sciences
Key Investors in Cyted Health
The Morningside Group
Founded in 1986 by the Chan family, this firm provides venture capital and private equity, leveraging deep industry knowledge and a strong commitment to social responsibility.
British Business Bank
A government-backed entity focused on increasing the supply of credit to small and medium-sized enterprises while providing essential business advisory services.
BGF
Headquartered in London, BGF is a prominent investor in the UK, supporting a diverse range of growing companies across various sectors and development stages.
What's next for Cyted Health?
Looking ahead, the strategic deployment of the $43.5M capital will likely focus on the commercialization of Cyted Health's diagnostic pipeline and the expansion of its clinical trial infrastructure. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward regulatory milestones and the integration of its technology into standard clinical practice across international markets. The backing from high-profile institutional investors provides not only the necessary liquidity for rapid scaling but also the strategic guidance required to navigate the complexities of the global healthcare market. Future growth will be predicated on the company's ability to maintain its technological edge while demonstrating clear clinical and economic value to stakeholders, including hospitals, insurers, and patients alike.
See full Cyted Health company page
